Peer Review History

Original SubmissionMay 1, 2026

Attachments
Attachment
Submitted filename: ReviewerResponse_MRBKGJLJ.pdf
Decision Letter - Samuel V. Scarpino, Editor, Juan Gonzalo Barajas-Ramirez, Editor

PCSY-D-26-00061

Are fast test results preferable to high test sensitivity in contact-tracing strategies?

PLOS Complex Systems

Dear Dr. Juul,

Thank you for submitting your manuscript to PLOS Complex Systems. After careful consideration, we feel that it has merit but does not fully meet PLOS Complex Systems's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 09 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at complexsystems@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pcsy/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

* A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below.

* A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

* An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors.

We look forward to receiving your revised manuscript.

Kind regards,

Juan Gonzalo Barajas-Ramirez

Academic Editor

PLOS Complex Systems

Samuel V. Scarpino

Section Editor

PLOS Complex Systems

Hocine Cherifi

Editor-in-Chief

PLOS Complex Systems

Journal Requirements:

1. Please amend your detailed Financial Disclosure statement. This is published with the article. It must therefore be completed in full sentences and contain the exact wording you wish to be published.

i. Please clarify all sources of financial support for your study. List the grants, grant numbers, and organizations that funded your study, including funding received from your institution. Please note that suppliers of material support, including research materials, should be recognized in the Acknowledgements section rather than in the Financial Disclosure.

ii. State the initials, alongside each funding source, of each author to receive each grant. For example: "This work was supported by the National Institutes of Health (####### to AM; ###### to CJ) and the National Science Foundation (###### to AM)."

iii. State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

iv. If any authors received a salary from any of your funders, please state which authors and which funders.

2. Please send a completed 'Competing Interests' statement, including any COIs declared by your co-authors. If you have no competing interests to declare, please state "The authors have declared that no competing interests exist". Otherwise please declare all competing interests beginning with the statement "I have read the journal's policy and the authors of this manuscript have the following competing interests:"

3. We ask that a manuscript source file is provided at Revision. Please upload your manuscript file as a .doc, .docx, .rtf or .tex.

4. Please upload separate figure files in .tif or .eps format. Also, remove the figures from your manuscript file but keep the legends.

For more information about figure files please see our guidelines:

https://journals.plos.org/complexsystems/s/figures

https://journals.plos.org/complexsystems/s/figures#loc-file-requirements

5. Please provide an Author Summary. This should appear in your manuscript between the Abstract (if applicable) and the Introduction, and should be 150–200 words long. The aim should be to make your findings accessible to a wide audience that includes both scientists and non-scientists. Sample summaries can be found on our website under Submission Guidelines:

https://journals.plos.org/complexsystems/s/submission-guidelines#loc-parts-of-a-submission

6. We notice that your supplementary figures and tables are included in the manuscript file. Please remove them and upload them with the file type 'Supporting Information'. Please ensure that each Supporting Information file has a legend listed in the manuscript after the references list.

If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Additional Editor Comments (if provided):

The reviewers consider the work in the revised manuscript to be improved over the previous submission. And that is within the scope of PLOS CS. However, a set of additional recommendations is made to improve the manuscript. Please prepare a revised version of the manuscript incorporating the comments of Reviewer 2.

[Note: HTML markup is below. Please do not edit.]

Reviewers' Comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does this manuscript meet PLOS Complex Systems’s publication criteria?>

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?-->?>

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

Reviewer #1:  I think this manuscript is revised version based on the reports of previous referees, and this revised one has addressed the previous quesitons, and the current version technically meets the publication criteria.

Reviewer #2:  The manuscript presents a study of the trade-off between test speed and sensitivity during testing, tracing, and isolation in an epidemic. The authors seek to inform the quandary in deciding between diagnostic tests, whether faster less-accurate tests or slower highly-accurate tests should be prioritised in contact-tracing strategies towards transmission reduction. Using a branching-process model and simulation outcomes, the authors conclude, among others, that rapid less sensitive tests can reduce transmission more than slower accurate tests, especially when contact tracing is relatively efficient and the delay for slow tests is high. Although not radically novel, the study contributes to a timely issue with continued relevance beyond COVID-19, in that the framework is general enough to adapt to any respiratory pathogen where rapid and accurate tests present a speed/sensitivity dynamic. The manuscript meets the PLOS Complex Systems publication criteria. It is technically sound, and describes methodologically and ethically sound research with conclusions drawn based on the data presented. The analysis performed is reasonable and the code underlying the findings of the manuscript is available at https://github.com/MoRahITU/TestTraceTradeoff. The manuscript is presented intelligibly and in standard English. The writing is comprehensible and the communication is generally logical. I recommend acceptance after reasonably addressing the following comments.

A. Major Comments

1. Line 192: The choice of the negative binomial mean parameter is described as "slightly lower than estimated in early stages of the pandemic”. Considering the range of R0 estimates in the literature (see references 28, 29 in the study), the authors should justify the R0 = 2 choice more explicitly since lower R0 relatively eases the epidemic control and can potentially affect where the breaking point lines fall.

2. Lines 293-294: “For clarity, all heatmaps have been smoothed with a Gaussian filter.”

Kernel bandwidth is not mentioned in the application of the Gaussian smoothing to the heatmaps and it is also not clear if the smoothing impacts the break-point contours. The smoothing parameters should be reported and confirmed that the contour positions are robust to the parameter choice(s).

3. Line 365: Can the k secondary cases equal infinity? The upper-bound of the interval may have to be “)” instead of “]”.

4. Line 202; 571-575: The authors assume a perfect slow test sensitivity; thus, Se = 1. While the study notes that the assumption, among others, favours the slow test, real-world PCR sensitivity in contact tracing is meaningfully less than 1, particularly in early infection. The authors should incorporate at least a supplementary analysis where slow test sensitivity Se <1; for instance, 0.85 - 0.95, which is consistent with real-world performance of PCR reported in symptomatics, and show how that shifts the breaking point lines.

5. In equation 5, the p_traceEff expression contains p_validtace, with the latter also being a function of delta and other model parameters. Given the authors’ indication of absence of a closed-form for p-validtrace, yet, reporting the degree of sensitivity of the analytical R_eff predictions to the numerical estimate of p_validtrace will be useful.

6. Lines 558-570: The observation of the performance equivalence of symptom-based self-isolation for 4-5 days and perfect-sensitivity zero-TAT test in the absence of contact tracing, is striking and underappreciated in public health. While presented almost as an aside, the remark deserves more highlighting (concise elaboration), perhaps with explicit caveat about reduced specificity during COVID-19 due to the suppression of other respiratory illnesses—which the authors mention but can foreground more.

7. Line 616-625: The authors argue that a contact-tracing delay is mathematically equivalent to a longer test result waiting time, and thus the study implicitly models the former. While that may hold in a theoretical sense, the argument elides a practical issue that, in a stressed testing system, TAT and tracing delays rise simultaneously and possibly non-linearly. However, while the two are correlated in pandemic stress, which is the real-world scenario of interest to the authors, the study presents the two as independent levers. The work will be considerably strengthened by a relevant scenario analysis or a careful discussion of the co-dependence.

8. Line 586-590; 890: In Appendix B, the implementation of the sensitivity over the infectious period (weighting scheme equation S1) is described as “simple and naive”. The authors indicate that the assumption that individuals have identical test-sensitivity curves tied to the same infectiousness profile is contestable as “overly simple” or “improbable”. However, Figure 3, coupled with the assertion that rapid tests are preferable for TATs greater than 4 days “for almost all levels of contact tracing” is drawn from that same analysis. The authors should either strengthen the model justification by comparison to trajectories of empirical viral load or reasonably relegate the certainty of conclusions drawn from Figure 3 relative to those from the constant-sensitivity analysis.

9. Lines 637-644: The authors note that only forward contact tracing is modelled and acknowledge that it biases the results against rapid tests that rely on tracing efforts. Considering that backward contact tracing has been shown in some network structures (cited references 46-54) to be substantially more efficient, and given that rapid antigen tests were sometimes particularly proposed to enable higher-frequency screening (not just contact tracing), the study would be enhanced by a discussion of which of its conclusions are robust to this assumption and which are most sensitive to it. Thus, the forward-only contact testing limitation presents asymmetric implications which require further discoursing.

10. Lines 994-995: The study acknowledges that the effective tracing probability (p_traceEff) involves p_validtrace, which according to the authors, has no closed-form and is inferred from simulations. The use of the simulation outputs to evaluate an analytical expression which is supposed to validate the simulations is circular and has not been discussed sufficiently. A clearer explanation of exactly what is being validated against what will be beneficial.

11. The manuscript does not discuss asymptomatic individuals and testing demand in any strategic regard. Rapid antigen tests were widely used for asymptomatic screening (e.g., workplace and school programmes), and not just for symptomatic contact tracing. The model, by design, only has asymptomatic individuals tested via contact tracing. This scope limitation should be stated clearly at the outset, and not just implied through the model description.

12. In Figure 1E, distinguishing the breaking-point lines for 8 and 10-day TATs from the 6-day line is visually over-exacting. The use of dashed and solid lines; adjusting colours for accessibility; or any visual intervention to ease distinctions may be considered by the authors.

13. The authors have provided the code for the work at https://github.com/MoRahITU/TestTraceTradeoff

Meanwhile, clicking on all “plot_definitions.py” files produces “An error occurred” feedback and should be resolved.

B. Minor Comments

1. Lines 24-27: In the definition for Test turnaround time (test TAT), the statement “How long it takes from a person orders a test to the result of the test arrives and contact tracing begins.” reads incomplete.

2. Line 92: There are two periods after “McAllon et al”

3. Line 377: Contains a duplication of “the” in “how much the the initial R0 is reduced".

4. Line 567-570: There must be a period after “isolation”. Also, the following statement reads incomplete: “However, during the Covid-19 pandemic a massive reduction in other respiratory diseases was observed, meaning that people experienced symptoms would be likely to be infected.

5. Line 988: The text extract “we know for sure that”, while understandable, does not read/sound scientific.

6. A thorough editorial pass should resolve all other writing and formatting issues.

**********

what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review?  If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

Figure resubmission:

After uploading your figures to PLOS’s NAAS tool - https://ngplosjournals.pagemajik.ai/artanalysis, NAAS will process the files provided and display the results in the "Uploaded Files" section of the page as the processing is complete. If the uploaded figures meet our requirements (or NAAS is able to fix the files to meet our requirements), the figure will be marked as "fixed" above. If NAAS is unable to fix the files, a red "failed" label will appear above. When NAAS has confirmed that the figure files meet our requirements, please download the file via the download option, and include these NAAS processed figure files when submitting your revised manuscript.

Reproducibility:

To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Revision 1

Attachments
Attachment
Submitted filename: Response to Reviewers.pdf
Decision Letter - Samuel V. Scarpino, Editor, Juan Gonzalo Barajas-Ramirez, Editor

Are fast test results preferable to high test sensitivity in contact-tracing strategies?

PCSY-D-26-00061R1

Dear Dr. Juul,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at https://www.editorialmanager.com/pcsy/ click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. For questions related to billing, please contact billing support at https://plos.my.site.com/s/.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact complexsystems@plos.org.

Kind regards,

Juan Gonzalo Barajas-Ramirez

Academic Editor

PLOS Complex Systems

Additional Editor Comments (optional):

Reviewers are satisfied with the inproved version of the mnauscript and have no further recomendations.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

--------------------

publication criteria?>

Reviewer #1: Yes

Reviewer #2: Yes

--------------------

3. Has the statistical analysis been performed appropriately and rigorously?-->?>

Reviewer #1: Yes

Reviewer #2: Yes

--------------------

4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: Yes

--------------------

5. Is the manuscript presented in an intelligible fashion and written in standard English?<br/><br/>PLOS Complex Systems does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->?>

Reviewer #1: Yes

Reviewer #2: Yes

--------------------

Reviewer #1: I have no further comments as I decladed in the previous round.

Reviewer #2: The review comments have been reasonably addressed by the authors. The revised manuscript is recommended for publication.

--------------------

what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review?  If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

Reviewer #2: No

--------------------

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .